Skip to main content

LCD L33438: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)

LCD L33438, Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot), is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-07-18 and first in force 2015-10-01. The policy text runs 423 words, and its billing and coding article A56531 lists 72 ICD-10-CM codes that support medical necessity for 1 procedure code. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-07-18
Original effective
2015-10-01
Policy text
423 words
Covered ICD-10 codes (articles)
72

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33438
ContractContractorTypeStates
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56531: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56531 (Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A56531: Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot) (Billing and Coding, effective 2024-10-01)

Covered ICD-10-CM codes
72
7 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56531
ICD-10-CMDescription (FY2027)
C25.4Malignant neoplasm of endocrine pancreas
C26.0Malignant neoplasm of intestinal tract, part unspecified
C37Malignant neoplasm of thymus
C7A.010Malignant carcinoid tumor of the duodenum
C7A.011Malignant carcinoid tumor of the jejunum
C7A.012Malignant carcinoid tumor of the ileum
C7A.019Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.020Malignant carcinoid tumor of the appendix
C7A.021Malignant carcinoid tumor of the cecum
C7A.022Malignant carcinoid tumor of the ascending colon
C7A.023Malignant carcinoid tumor of the transverse colon
C7A.024Malignant carcinoid tumor of the descending colon
C7A.025Malignant carcinoid tumor of the sigmoid colon
C7A.026Malignant carcinoid tumor of the rectum
C7A.029Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.090Malignant carcinoid tumor of the bronchus and lung
C7A.091Malignant carcinoid tumor of the thymus
C7A.092Malignant carcinoid tumor of the stomach
C7A.093Malignant carcinoid tumor of the kidney
C7A.094Malignant carcinoid tumor of the foregut, unspecified
C7A.095Malignant carcinoid tumor of the midgut, unspecified
C7A.096Malignant carcinoid tumor of the hindgut, unspecified
C7A.098Malignant carcinoid tumors of other sites
C7A.1Malignant poorly differentiated neuroendocrine tumors

Procedure codes: J2353 (Injection, octreotide, depot form for intramuscular injection, 1 mg).

Coverage indications, limitations and medical necessity

Octreotide acetate is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone, somatostatin. Octreotide acetate for injectable suspension is a long-acting dosage form containing octreotide. It maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form, octreotide acetate, with the added feature of slow release of octreotide from the site of injection, reducing the need for frequent administration.

Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (severe diarrhea and flushing) and vasoactive intestinal peptide (VIP) secreting adenomas (profuse watery diarrhea).

Octreotide substantially reduces, and in many cases, can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.

• Octreotide acetate for injectable suspension is Food and Drug Administration (FDA) approved for the reduction of growth hormone and IGF-1 in patients with acromegaly, for whom medical treatment is appropriate, and who have been shown to respond to and can tolerate short-acting subcutaneous octreotide acetate. The goal of treatment is to reduce growth hormone and IGF-1 levels to normal. It is also used in patients who have had an inadequate response to surgery or in those for whom surgical resection is not an option. It is also used in patients who have received radiation and have had an inadequate therapeutic response.

• It is FDA approved for the suppression of severe diarrhea and flushing associated with malignant carcinoid syndrome in patients in whom initial treatment with short-acting, subcutaneous octreotide acetate has been effective and tolerated.

• It is FDA approved for long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with short-acting, subcutaneous octreotide acetate has been shown to be effective.

• The approved route of administration of octreotide acetate for injectable suspension is intragluteally, and it must be administered under the direct supervision of a physician.

• Octreotide acetate for injectable suspension is covered only when it is used according to FDA guidelines.

• A trial of therapy using the short-acting, subcutaneous form of octreotide acetate is a prerequisite prior to administering the long-acting octreotide acetate suspension. However, the short-acting, subcutaneous form of octreotide is noncovered by this A/B MAC, because it is self-administrable.

• Octreotide is covered for chemotherapy-induced diarrhea (CID) when oral antidiarrheal medications, such as loperamide, have become ineffective.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2024-07-18
Last reviewed by the contractor
2024-06-11
MCD version
47
Derived from
L31713

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L33438 cover?

Octreotide acetate is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone, somatostatin. Octreotide acetate for injectable suspension is a long-acting dosage form containing octreotide. It maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form, octreotide acetate, with the added… The full 423-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L33438 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33438?

The companion billing and coding article A56531 lists 72 ICD-10-CM codes in 7 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L33438?

A denial under LCD L33438 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56531's 72 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.